Funding for this research was provided by:
Mitsubishi Tanabe Pharmaceutical
Text and Data Mining valid from 2018-04-16
Received: 8 January 2018
Accepted: 7 March 2018
First Online: 16 April 2018
Ethics approval and consent to participate
: Written informed consent for this study was obtained from all participating patients. This study was designed in accordance with the Helsinki declaration and was approved by the ethics committee of Kyoto University Graduate School and Faculty of Medicine (R0357).
: All of the listed authors declared the consent for publication.
: The Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, and four pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, and AYUMI Pharmaceutical Co.). KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd. This study is conducted as investigator initiate study. HI has received a research grant and/or speaker fee from Bristol-Myers, Astellas, and Eli Lily. MH has received research grants from Astellas and Daiichi-Sankyo. MT has received research grants from Astellas, Abbvie, Pfizer, and Taisho-Toyama. MF and SM declared no conflicts of interest. The sponsors were not involved in the study design; in the collection, analysis, and interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.